Prospects for and barriers to a fungal vaccine

Expert Opinion on Biological Therapy

Volumn 7, Issue 12, 2007, Pages 1785-1788

  Spellberg, Brad ^a,b  

^a HARBOR UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Candida; Fungal; Vaccine

Indexed keywords

ANTIBIOTIC AGENT; CORTICOSTEROID; FUNGUS VACCINE;

CANDIDA; CANDIDIASIS; CLINICAL TRIAL; FUNGUS ISOLATION; HIGH RISK PATIENT; HUMAN; IMMUNE RESPONSE; MYCOSIS; NONHUMAN; REVIEW; VACCINATION;

ANIMALS; CANDIDIASIS; CLINICAL TRIALS AS TOPIC; DRUGS, INVESTIGATIONAL; EXPERT TESTIMONY; FUNGAL VACCINES; HUMANS; MICE; RISK FACTORS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

CANDIDA;

EID: 37049028771     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.7.12.1785     Document Type: Review

References (19)

1. PERLROTH J, CHOI B, SPELLBERG B: Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med. Mycol. (2007) 45(4):321-346.
2. SPELLBERG B, FILLER SG, EDWARDS JE Jr: Current treatment strategies for disseminated candidiasis. Clin. Infect. Dis. (2006) 42:244-251.
3. WILSON LS, REYES CM, STOLPMAN M et al.: The direct cost and incidence of systemic fungal infections. Value Health (2002) 5(1):26-34.
4. WISPLINGHOFF H, BISCHOFF T, TALLENT SM et al.: Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin. Infect. Dis. (2004) 39(3):309-317.
5. TOROSANTUCCI A, BROMURO C, CHIANI P et al.: A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. (2005) 202(5):597-606.
6. YANG Q, WANG L, LU DN et al.: Prophylactic vaccination with phage-displayed epitope of C. albicans elicits protective immune responses against systemic candidiasis in C57BL/6 mice. Vaccine (2005) 23(31):4088-4096.
7. SPELLBERG BJ, IBRAHIM AS, AVANESIAN V et al.: Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J. Infect. Dis. (2006) 194(2):256-260.
8. SPELLBERG BJ, IBRAHIM AS, AVENISSIAN V et al.: The anti-Candida albicans vaccine composed of the recombinant N terminus of Als1p reduces fungal burden and improves survival in both immunocompetent and immunocompromised mice. Infect. Immun. (2005) 73(9):6191-6193.
9. IBRAHIM AS, SPELLBERG BJ, AVANESIAN V et al.: The anti-Candida rAls1p-N vaccine is broadly active against disseminated candidiasis. Infect. Immun. (2006) 74:3039-3041.
10. IBRAHIM AS, SPELLBERG BJ, AVENISSIAN V et al.: Vaccination with recombinant N-terminal domain of Als1p improves survival during murine disseminated candidiasis by enhancing cell-mediated, not humoral, immunity. Infect. Immun. (2005) 73(2):999-1005.
11. DOS SANTOS SDE S, LOPES MH, SIMONSEN V et al.: Haemophilus influenzae type B immunization in adults infected with the human immunodeficiency virus. AIDS. Res. Hum. Retroviruses (2004) 20(5):493-496.
12. DOCKRELL DH, POLAND GA, STECKELBERG JM et al.: Immunogenicity of three Haemophilus influenzae type B protein conjugate vaccines in HIV seropositive adults and analysis of predictors of vaccine response. Vaccine (1999) 17(22):2779-2785.
13. LEVIN MJ, GERSHON AA, WEINBERG A et al.: Immunization of HIV-infected children with varicella vaccine. J. Pediatr. (2001) 139(2):305-310.
14. TEDALDI EM, BAKER RK, MOORMAN AC et al.: Hepatitis A and B vaccination practices for ambulatory patients infected with HIV. Clin. Infect. Dis. (2004) 38(10):1478-1484.
15. SINSALO M, AITTONIEMI J, KAYHTY H et al.: Haemophilus influenzae type B (HiB) antibody concentrations and vaccination responses in patients with chronic lymphocytic leukaemia: predicting factors for response. Leuk. Lymphoma (2002) 43(10):1967-1969.
16. NORDOY T, AABERGE IS, HUSEBEKK A et al.: Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and Streptococcus pneumoniae. Med. Oncol. (2002) 19(2):71-78.
17. LEUNG TF, LI CK, HUNG EC et al.: Immunogenicity of a two-dose regime of varicella vaccine in children with cancers. Eur. J. Haematol. (2004) 72(5):353-357.
18. KLUGMAN KP, MADHI SA, HUEBNER RE et al.: A trial of a 9-valent pneumococcal conjugate vaccine in children with and those without HIV infection. N. Engl. J. Med. (2003) 349(14):1341-1348.
19. MADHI SA, KUWANDA L, CUTLAND C et al.: The impact of a 9-valent pneumococcal conjugate vaccine on the public health burden of pneumonia in HIV-infected and -uninfected children. Clin. Infect. Dis. (2005) 40(10):1511-1518.